迪哲医药2025年上半年净利润亏损3.77亿元

Core Viewpoint - Dige Pharmaceutical reported a significant increase in revenue for the first half of 2025, but continued to face net losses [1] Financial Performance - The company achieved an operating revenue of 355 million yuan, representing a year-on-year growth of 74.4% [1] - The net loss attributable to shareholders was 377 million yuan, compared to a loss of 345 million yuan in the same period last year [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 419 million yuan, compared to a loss of 381 million yuan in the previous year [1]